Biotech Values

[DewDiligence]

AMLN/ALKS/LLY—How’s this for a rationalization?

http://www.bloomberg.com/news/2011-03-03/amylin-alkermes-fall-after-bydureon-doesn-t-best-victoza-in-diabetes-test.html

“We didn’t hit the primary endpoint, but the results do actually reinforce the fact that this product has a very robust effect,” Amylin Chief Executive Officer Dan Bradbury said in a telephone interview today.

Stop spinning, Dan. These results are an unmitigated calamity for your company.